Clinical trial · Interventional
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions
NCT00029224CI-TRIAL-00006166completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| zoledronic acid | Drug | Zoledronic Acid | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Pain score assessed by change from baseline
Secondary outcomes (3)
- measure
- Quality of life
- measure
- Time in infusion chair
- measure
- Safety assessed by adverse events (AEs)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria * Signed informed consent * Greater than 18 years of age * Proof of breast cancer, multiple myeloma or prostate cancer * Diagnosis of at least one cancer-related bone lesion * If patient is of child-bearing potential, negative pregnancy test and on a medically recognized form of contraception * ECOG performance status of 0,1 or 2 * Ability to read, understand and write English or Spanish language * Normal renal function * Corrected serum calcium equal to or greater than 8mg/dl Exclusion Criteria * clinically symptomatic brain metastases * hypersensitivity to Zometa or other bisphosphonates * pregnant or lactating
References
Publications (0)
Data not yet available
No reference posted for this study.